List of Excipients in Branded Drug CLINDAMYCIN AND BENZOYL PEROXIDE

« Back to Dashboard

Generic Drugs Containing CLINDAMYCIN AND BENZOYL PEROXIDE

Company	Ingredient	NDC	Excipient
NorthStar RxLLC	clindamycin and benzoyl peroxide	16714-984	CARBOMER HOMOPOLYMER TYPE C
NorthStar RxLLC	clindamycin and benzoyl peroxide	16714-984	DOCUSATE SODIUM
NorthStar RxLLC	clindamycin and benzoyl peroxide	16714-984	EDETATE DISODIUM
NorthStar RxLLC	clindamycin and benzoyl peroxide	16714-984	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in CLINDAMYCIN AND BENZOYL PEROXIDE?

# Of NDCs	Excipient
3	CARBOMER HOMOPOLYMER TYPE C
3	DOCUSATE SODIUM
3	EDETATE DISODIUM
3	SODIUM HYDROXIDE

Clindamycin and Benzoyl Peroxide Excipient Strategy and Commercial Opportunities

Last updated: October 8, 2026

Clindamycin and benzoyl peroxide is a mature topical acne combination with limited composition-of-matter protection and continuing commercial value in differentiated formulations. The strongest opportunities are not new active ingredients. They are improved stability, lower irritation, better cosmetic acceptability, simplified dosing, packaging innovation, and compliant generic or branded-generic execution.

The core commercial product is a topical gel combining clindamycin phosphate, typically equivalent to 1.2% clindamycin, with 5% benzoyl peroxide. Branded reference products include Duac and BenzaClin, although product composition, manufacturing configuration, labeling, and reference-product status must be assessed separately in each jurisdiction. FDA labeling identifies the combination as a prescription topical treatment for acne vulgaris [1,2].

What is the commercial profile of clindamycin and benzoyl peroxide?

Clindamycin reduces Cutibacterium acnes and inflammatory acne lesions. Benzoyl peroxide has antimicrobial and keratolytic activity and reduces the risk of clindamycin-resistant organisms. The combination is generally positioned for inflammatory acne, including papules and pustules.

Attribute	Typical combination
Active 1	Clindamycin phosphate, equivalent to 1.2% clindamycin
Active 2	Benzoyl peroxide, 5%
Dosage form	Topical aqueous gel
Main indication	Acne vulgaris
Regulatory status	Prescription drug in the United States
Primary users	Adolescents and adults
Main commercial constraints	Irritation, instability, packaging, antibiotic stewardship
Main differentiation levers	Vehicle, sensory profile, stability, dosing, package, price

The product category is mature, but acne is large, chronic and refill-driven. Commercial demand is supported by primary-care prescribing, dermatology use, adolescent treatment and combination therapy preferences. The market is price-sensitive because multiple generic products are available or can be developed through abbreviated regulatory pathways.

What excipients are used in clindamycin and benzoyl peroxide gels?

The excipient system must support two chemically and physically different active ingredients. Clindamycin phosphate is water soluble and ionic. Benzoyl peroxide is poorly water soluble, oxidizing and sensitive to formulation environment, packaging and heat. A useful vehicle must suspend or disperse benzoyl peroxide while maintaining clindamycin uniformity and acceptable skin feel.

Representative product labels identify excipient classes including water, carbomer or another acrylic rheology modifier, glycerin or another humectant, poloxamer, methylparaben in some products, and a pH-adjusting base such as sodium hydroxide or potassium hydroxide [1,2].

Which excipient functions are commercially important?

Excipient function	Typical options	Strategic purpose
Vehicle	Purified water, hydroalcoholic or polyol-containing system	Solubilizes clindamycin and carries suspended benzoyl peroxide
Rheology control	Carbomer, acrylates crosspolymer, cellulose derivative	Controls suspension, spreadability and dosing uniformity
Humectancy	Glycerin, propylene glycol, glycols	Reduces drying and improves application feel
Surfactancy	Poloxamer, nonionic surfactant	Improves wetting and dispersion of benzoyl peroxide
pH adjustment	Sodium hydroxide, potassium hydroxide, buffers	Controls carbomer viscosity and active stability
Preservation	Parabens or alternative preservative systems	Controls microbial growth in aqueous products
Chelation	EDTA or equivalent, where justified	May reduce metal-catalyzed oxidation
Packaging compatibility	Low-permeability plastic, laminate or airless system	Limits oxygen, moisture loss, adsorption and contamination

The excipient strategy should be developed around performance targets rather than inactive-ingredient substitution alone. A generic formulation must demonstrate pharmaceutical equivalence and bioequivalence or another FDA-accepted equivalence approach. A new branded formulation has more freedom but faces additional clinical, regulatory and manufacturing costs.

How should benzoyl peroxide stability drive excipient selection?

Benzoyl peroxide is the principal formulation-risk component. It can decompose through heat, light, metal contamination and unsuitable pH or excipient interactions. Decomposition can reduce potency and create changes in color, odor, viscosity or particle properties.

A development program should control:

1. Benzoyl peroxide particle size and distribution.
2. Wetting and deagglomeration.
3. Metal-ion exposure.
4. Oxygen and temperature exposure.
5. pH and ionic strength.
6. Container permeability.
7. Mixing shear and scale-up conditions.
8. Microbial quality in the aqueous vehicle.

Carbomer systems are commercially attractive because they provide suspension and gel structure at low use levels. Their performance can change with neutralization, electrolytes, surfactants and manufacturing order. Excessive viscosity can impair dispensing and spreading. Insufficient viscosity can produce sedimentation, dose nonuniformity and poor consumer acceptance.

Nonionic wetting agents can improve benzoyl peroxide dispersion while limiting interaction with clindamycin. Surfactant selection must be evaluated for irritation, foam, odor, preservative performance and long-term chemical stability. Glycerin can improve moisturization but may increase tackiness. Propylene glycol can improve solvent properties and spreadability but may increase stinging in sensitive users.

What formulation opportunities exist beyond a conventional aqueous gel?

Low-irritation and barrier-supportive formulations

Benzoyl peroxide frequently causes dryness, erythema, peeling and burning. A differentiated vehicle can reduce perceived irritation through controlled release, humectant balance, emollient inclusion, lower surface residence or improved dispersion.

Potential approaches include:

• Reduced free benzoyl peroxide at the skin surface while maintaining total dose.
• Polyol-based systems that reduce rapid drying.
• Barrier-supportive excipients such as selected emollients or skin-compatible lipids.
• Lower-irritation surfactant systems.
• pH optimization within the acceptable performance range.
• Dual-chamber or activation-on-use systems that minimize degradation.

These approaches require evidence that the change improves tolerability without reducing antimicrobial activity, dose uniformity or stability.

Improved cosmetic acceptability

The most commercially relevant attributes are often spreadability, residue, pilling, odor, whitening, tack and compatibility with sunscreen or makeup. A translucent, fast-drying, non-pilling gel can compete effectively even when the active ingredients and concentrations are unchanged.

Commercial claims must remain consistent with the approved label. “Non-comedogenic,” “oil-free,” “fragrance-free” and “sensitive-skin” positioning may be valuable, but each claim requires substantiation and jurisdiction-specific review.

Preservative-reduced or preservative-free products

Aqueous topical products require strong microbial-control strategies. Preservative reduction can support sensitive-skin positioning, but it shifts risk to manufacturing controls, package design, water activity and in-use stability.

Airless pumps, unit-dose packages and closed dispensing systems can reduce contamination and support preservative-free claims. They also increase component cost and device-development requirements.

Lower-strength benzoyl peroxide products

A lower benzoyl peroxide concentration may offer a tolerability advantage, but it changes the regulatory and clinical profile. The commercial value depends on whether the product is positioned as a separate strength, a maintenance product or a sensitive-skin option. A lower-strength product may also reduce bleaching and irritation concerns.

Alternative dosage forms

Potential dosage forms include:

• Pumped gel.
• Lotion or cream.
• Emulsion-gel.
• Foam.
• Hydrogel.
• Single-use sachet.
• Two-part product mixed immediately before application.

Each format creates a different balance between stability, manufacturing cost, user convenience and regulatory burden. Foam and emulsion systems may improve sensory performance but often require more complex manufacturing and packaging.

What patents protect clindamycin and benzoyl peroxide products?

The basic active combination is mature. Broad composition patents covering clindamycin plus benzoyl peroxide are likely to have limited remaining commercial value in the United States where relevant early patents have expired or reached the end of their enforceable terms. Current protection is more likely to arise from narrower claims involving:

• Specific excipient ratios.
• Particle-size distributions.
• Gel microstructure.
• Stabilization systems.
• Manufacturing sequences.
• Container-closure systems.
• Separate-compartment packaging.
• Controlled-release delivery.
• Specific methods of treating acne.
• New strengths or dosage forms.

Patent clearance must distinguish between the active combination, the finished formulation, the manufacturing process and the package. A competitor can avoid a formulation claim while still infringing a process or device claim.

What is the Orange Book status of clindamycin and benzoyl peroxide?

The FDA Orange Book lists approved drug products and patent or exclusivity information where applicable. Product status can differ between branded reference products and later abbreviated applications. Orange Book review should confirm:

• The precise reference listed drug.
• NDA number and dosage form.
• Listed patents and delisting status.
• Patent expiration dates.
• Whether a patent is listed for the specific strength and formulation.
• Any statutory exclusivity.
• Whether an ANDA applicant has filed a Paragraph IV certification.

The Orange Book is not a complete global patent register and does not capture every formulation, manufacturing or foreign patent. FDA Orange Book data should be paired with USPTO records, patent-family analysis, FDA approval letters and court dockets [3,4].

When does clindamycin and benzoyl peroxide lose exclusivity?

The active ingredients do not have meaningful new-molecule exclusivity as a combination product. Commercial exclusivity generally depends on listed formulation or method-of-use patents, regulatory exclusivity, trademarks, manufacturing know-how and market access.

Exclusivity category	Relevance to this combination
New chemical entity exclusivity	Generally not applicable
Five-year NCE exclusivity	Not applicable to established actives
Three-year new clinical investigation exclusivity	Possible only if qualifying new clinical work supports a new approval
Orphan exclusivity	Not applicable to acne
Pediatric exclusivity	Possible if separately awarded, but not a default assumption
Listed formulation patents	Potentially relevant for branded or improved products
Method-of-use patents	May cover a defined patient population or treatment regimen
Trade secrets	Important for dispersion, scale-up and stability processes
Trademarks and trade dress	Relevant to branded-generic differentiation

A generic launch can occur after approval if no enforceable patent blocks launch, after a Paragraph IV litigation outcome, after settlement terms permit entry, or after a licensed entry date. The exact launch date depends on the product’s ANDA status, certifications, court orders and commercial strategy.

Which companies are challenging the reference products?

Generic manufacturers commonly target established topical acne combinations through ANDAs. The competitive field can include large generic companies, specialty dermatology companies and contract development partners. The existence of an approved generic does not establish that all formulation, device or process patents have been cleared.

A reliable competitor assessment should compare:

• ANDA approval status.
• Reference listed drug selection.
• Product concentration and dosage form.
• Ready-to-use versus reconstituted presentation.
• Package configuration.
• Patent certifications.
• Litigation and settlement terms.
• Wholesale acquisition cost and payer coverage.
• Pharmacy substitution potential.

Because product-level litigation and Paragraph IV data change over time, the operative record is the FDA Orange Book, FDA approval database and federal court docket rather than historical launch announcements [3-5].

What formulation patents could create a new commercial moat?

The strongest patent opportunities are narrow, measurable and linked to a product advantage. Examples include claims directed to:

1. A benzoyl peroxide particle-size range that improves uniformity.
2. A specific carbomer and surfactant combination that prevents sedimentation.
3. A package that limits benzoyl peroxide degradation.
4. A two-compartment system that extends shelf life.
5. A formulation with defined rheology and spreadability.
6. A low-irritation composition supported by comparative clinical data.
7. A manufacturing process that produces a stable dispersion at commercial scale.
8. A controlled-release matrix that reduces irritation while preserving efficacy.

Patent strength improves when claims include objective parameters, robust examples and stability or clinical data. Weak claims that rely on broad excipient lists or routine substitutions are vulnerable to obviousness challenges.

What manufacturing and intellectual-property barriers affect market entry?

Manufacturing risk is concentrated in benzoyl peroxide handling, dispersion uniformity, microbial control, filling accuracy and packaging compatibility. Scale-up can change particle distribution, viscosity and air incorporation. Mixing order and shear must be defined in the control strategy.

Key barriers include:

• Qualification of pharmaceutical-grade benzoyl peroxide.
• Control of metal contamination.
• Validated cleaning for oxidizing material.
• Uniform filling of high-viscosity gel.
• Container-closure compatibility.
• Stability under long-term and accelerated conditions.
• In-use microbial testing.
• Preservative effectiveness testing.
• Transfer of the formulation between manufacturing sites.

Trade secrets can provide meaningful protection even where patents have expired. A process that consistently produces a stable, cosmetically acceptable gel may be difficult to replicate without development history and scale-up data.

How does clindamycin and benzoyl peroxide compare with other acne products?

Product category	Main advantage	Main limitation	Commercial opportunity
Clindamycin alone	Familiar antibiotic treatment	Resistance concern and monotherapy limitations	Low-cost generic
Benzoyl peroxide alone	No antibiotic resistance mechanism	Irritation and bleaching	OTC and prescription strengths
Clindamycin plus benzoyl peroxide	Combination antimicrobial activity	Irritation, antibiotic stewardship	Branded-generic and differentiated vehicle
Adapalene plus benzoyl peroxide	Retinoid plus antimicrobial therapy	Irritation and broader label complexity	Strong combination-product segment
Tretinoin combinations	Comedolytic and anti-inflammatory positioning	Stability and irritation	Premium dermatology products
Azelaic acid	Anti-inflammatory and pigment-related utility	Slower perceived response	Sensitive-skin and post-inflammatory hyperpigmentation positioning

Clindamycin-containing products face antibiotic stewardship pressure. A commercial strategy should support appropriate use, avoid unsupported long-duration claims and position benzoyl peroxide as part of resistance-management practice where consistent with applicable guidelines and labeling [6].

What licensing and partnership opportunities exist?

The most practical licensing opportunities are formulation and platform transactions rather than licenses to the active ingredients. Potential assets include:

• A stable, ready-to-use gel platform.
• A low-irritation benzoyl peroxide dispersion.
• A preservative-free package.
• A long-shelf-life product for hot and humid markets.
• A pediatric or adolescent-friendly delivery format.
• A process that reduces manufacturing cost.
• A dermatology portfolio combination with retinoids or antifungal products.

Potential counterparties include generic manufacturers, dermatology-focused pharmaceutical companies, contract development and manufacturing organizations, and regional licensees. Deal value will depend on freedom to operate, bioequivalence status, manufacturing readiness, patent term, market access and the ability to secure substitution.

What generic launch risks exist?

Generic-entry risk is high for a conventional 1.2%/5% gel with no meaningful differentiation. Price erosion can be rapid after multiple ANDA approvals. A sponsor can reduce exposure by using:

• A device or package that improves adherence.
• A differentiated vehicle with measurable tolerability benefits.
• A lower-irritation or preservative-reduced formulation.
• A higher-margin dermatology brand.
• Contract manufacturing scale.
• Regional registration and supply advantages.
• A patent portfolio covering formulation and process features.

Revenue exposure should be modeled under three scenarios: no generic entry, one generic entrant and multi-generic competition. The largest decline usually occurs after pharmacy substitution becomes routine rather than at the first approval.

Key Takeaways

• The commercial value of clindamycin and benzoyl peroxide lies in formulation execution, not active-ingredient novelty.
• Benzoyl peroxide stability, dispersion, irritation and packaging are the main technical priorities.
• Conventional composition patents provide limited long-term protection in a mature product category.
• New opportunities exist in low-irritation vehicles, preservative-reduced systems, airless packaging, alternative dosage forms and improved cosmetic performance.
• Orange Book review, ANDA status and Paragraph IV records are essential for U.S. launch planning.
• Manufacturing know-how can remain valuable after broad patents expire.
• A conventional generic gel has high price-competition risk; a differentiated vehicle can support stronger margins.

FAQs About Clindamycin and Benzoyl Peroxide Excipient Strategy

Can clindamycin and benzoyl peroxide be formulated without parabens?

Yes. A preservative-free product is possible if the package, manufacturing controls, formulation water activity and in-use microbial performance support the claim. The formulation must still meet applicable microbial and stability requirements.

Which excipient is most important for benzoyl peroxide suspension?

The rheology modifier is central, but suspension performance depends on the combined effect of the polymer, wetting agent, particle size, neutralization level and mixing process. No single excipient determines product quality.

Is a new vehicle eligible for an ANDA?

A formulation can qualify for an ANDA only if it meets the applicable requirements for pharmaceutical equivalence and bioequivalence to the reference listed drug. A material change in dosage form, route, strength or active release may require a different regulatory pathway.

Can packaging support patent protection for a topical acne product?

Yes. A package patent may cover a low-permeability container, airless pump, dual-chamber system, activation mechanism or dispensing structure. The claims must define a non-obvious technical arrangement and the product must use the claimed system.

Does benzoyl peroxide reduce clindamycin-resistance risk?

Benzoyl peroxide has activity against acne-associated bacteria and is used with topical antibiotics to reduce resistance selection. The clinical and regulatory significance depends on treatment duration, adherence and the approved product labeling. [6]

References

1. U.S. Food and Drug Administration. (2023). Duac clindamycin phosphate and benzoyl peroxide gel prescribing information.
2. U.S. Food and Drug Administration. (2023). BenzaClin clindamycin phosphate and benzoyl peroxide gel prescribing information.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and drug database resources.
5. U.S. Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System records.
6. American Academy of Dermatology. (2016). Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology, 74(5), 945-973.